PE20240817A1 - Mutantes de proteina f de rsv - Google Patents

Mutantes de proteina f de rsv

Info

Publication number
PE20240817A1
PE20240817A1 PE2023001148A PE2023001148A PE20240817A1 PE 20240817 A1 PE20240817 A1 PE 20240817A1 PE 2023001148 A PE2023001148 A PE 2023001148A PE 2023001148 A PE2023001148 A PE 2023001148A PE 20240817 A1 PE20240817 A1 PE 20240817A1
Authority
PE
Peru
Prior art keywords
protein
rsv
mutant
polypeptide
subtype
Prior art date
Application number
PE2023001148A
Other languages
English (en)
Inventor
Ye Che
Philip Ralph Dormitzer
Alexey Vyacheslavovich Gribenko
Luke David Handke
Avvari Krishna Prasad
Xiayang Qiu
Mark Edward Ruppen
Xi Song
Kena Anne Swanson
Srinivas Kodali
Xin Xu
KariAnn Sweeney Efferen
Ping Cai
Kristin Rachael Tompkins
Lorna del Pilar Nunez
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20240817A1 publication Critical patent/PE20240817A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a mutantes de una proteina F de RSV de tipo silvestre y del subtipo A o B, los cuales comprenden un polipeptido F1 y F2 y mutaciones de aminoacidos introducidas relativas a la proteina F de RSV de tipo silvestre, por ejemplo, un par de mutaciones de cisteina que consiste en: 103C y 148C. Asimismo, las posiciones de los aminoacidos de esta proteina estan numeradas de acuerdo a la SEQ ID NO: 1. Tambien, refiere a los usos de moleculas de acido nucleico y vectores que codifican a los presentes mutantes y composiciones farmaceuticas, que comprenden un primer y segundo mutante, en donde el extremo C-terminal del polipeptido F1 del primer mutante de la proteina F del RSV de subtipo A y el extremo C-terminal del polipeptido F1 del segundo mutante de la proteina F del RSV de subtipo B, esta cada uno enlazado a un dominio plegado de fibritina del fago T4.
PE2023001148A 2015-12-23 2016-12-09 Mutantes de proteina f de rsv PE20240817A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387270P 2015-12-23 2015-12-23
US201662421184P 2016-11-11 2016-11-11
PCT/IB2016/057502 WO2017109629A1 (en) 2015-12-23 2016-12-09 Rsv f protein mutants

Publications (1)

Publication Number Publication Date
PE20240817A1 true PE20240817A1 (es) 2024-04-18

Family

ID=57590746

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2023001147A PE20232039A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv
PE2018001128A PE20181354A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv
PE2023001148A PE20240817A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2023001147A PE20232039A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv
PE2018001128A PE20181354A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv

Country Status (17)

Country Link
US (5) US9950058B2 (es)
EP (1) EP3393512A1 (es)
JP (4) JP6817307B2 (es)
KR (3) KR102505354B1 (es)
CN (1) CN108738312A (es)
AU (4) AU2016379097C1 (es)
BR (1) BR112018010805A2 (es)
CA (2) CA2952131C (es)
CO (1) CO2018006301A2 (es)
IL (1) IL260203B1 (es)
MX (2) MX2018007622A (es)
PE (3) PE20232039A1 (es)
PH (1) PH12018501355A1 (es)
RU (1) RU2723039C2 (es)
SG (2) SG10202001389PA (es)
TW (3) TWI707866B (es)
WO (1) WO2017109629A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125172B2 (en) 2013-07-25 2018-11-13 Calder Biosciences Inc. Conformationally stabilized RSV pre-fusion F proteins
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
MX2019011869A (es) 2017-04-04 2020-01-09 Univ Washington Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
CN111405907A (zh) 2017-08-07 2020-07-10 考尔德生物科技有限公司 构象稳定的rsv预融合f蛋白
JP2021511356A (ja) 2018-01-29 2021-05-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 安定化ｒｓｖ ｆタンパク質およびその使用
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
JOP20210106A1 (ar) * 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN110054668B (zh) * 2019-04-25 2021-09-10 北京交通大学 一种呼吸道合胞病毒融合前f蛋白及其应用
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
US20220306697A1 (en) 2019-09-04 2022-09-29 University Of Washington Self-Assembling Protein Nanostructures Displaying Paramyxovirus and/or Pneumovirus F Proteins and Their Use
IL294059A (en) * 2019-12-23 2022-08-01 Mitsubishi Tanabe Pharma Corp Mutant rsv f protein and its use
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
CN112899214B (zh) * 2020-07-07 2023-08-04 湖南师范大学 废弃鱼鳞在制备各向异性基底中的应用
JP2022023814A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
JP2022023813A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN114685676B (zh) * 2020-12-28 2024-02-13 兰州生物制品研究所有限责任公司 一种重组蛋白及其表达方法、纯化方法及用途
JP2024509756A (ja) * 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆｂ抗原
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023208206A1 (zh) * 2022-04-29 2023-11-02 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
WO2024041773A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024093554A1 (zh) * 2022-11-04 2024-05-10 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
CN117487823A (zh) * 2023-09-28 2024-02-02 怡道生物科技(苏州)有限公司 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用
CN117304279B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304280B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304278B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117645655B (zh) * 2024-01-26 2024-05-24 普大生物科技(泰州)有限公司 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
CA2684578A1 (en) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2008154456A2 (en) 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
EA021393B1 (ru) * 2007-12-24 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Рекомбинантные антигены rsv
BRPI0915960A2 (pt) 2008-07-18 2019-09-24 Id Biomedical Corp antígenos de polipeptídeos do vírus sincicial respiratório qimérico
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
LT3067064T (lt) 2008-12-09 2020-09-10 Novavax, Inc. Modifikuoti rsv f baltymai ir jų panaudojimo būdai
JP5796011B2 (ja) * 2009-06-24 2015-10-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
SI2445526T1 (sl) * 2009-06-24 2016-08-31 Glaxosmithkline Biologicals S.A. Rekombinantni RSV antigeni
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
RU2540020C2 (ru) 2009-10-06 2015-01-27 Медиммьюн Лтд Молекула, специфически связывающаяся с rsv
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
PT2667892T (pt) 2011-01-26 2019-06-07 Glaxosmithkline Biologicals Sa Regime de imunização contra o vsr
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
ES2395677B1 (es) 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
BR112014007616A2 (pt) 2011-09-30 2017-04-04 Novavax Inc vacina de nanopartícula f de rsv recombinante para o vírus sincicial respiratório
CN104334188B (zh) 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
CN104853769A (zh) 2012-11-20 2015-08-19 葛兰素史密丝克莱恩生物有限公司 Rsv f融合前三聚体
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
MX2015013065A (es) 2013-03-13 2016-06-06 Us Health Proteinas f de rsv de prefusion y su uso.
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
AP2015008893A0 (en) 2013-06-17 2015-12-31 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
US10125172B2 (en) * 2013-07-25 2018-11-13 Calder Biosciences Inc. Conformationally stabilized RSV pre-fusion F proteins
US20150166610A1 (en) * 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US11324816B2 (en) * 2015-08-31 2022-05-10 Technovax, Inc. Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
US10496141B2 (en) 2016-03-17 2019-12-03 Qualcomm Incorporated System and method for intelligent thermal management in a system on a chip having a heterogeneous cluster architecture

Also Published As

Publication number Publication date
RU2020115606A (ru) 2020-06-29
IL260203A (en) 2018-07-31
CN108738312A (zh) 2018-11-02
RU2020115606A3 (es) 2020-11-23
TW201726709A (zh) 2017-08-01
TWI656130B (zh) 2019-04-11
AU2016379097B2 (en) 2019-08-22
SG11201804148TA (en) 2018-07-30
US10238732B2 (en) 2019-03-26
AU2021202522A1 (en) 2021-05-27
CA2952131A1 (en) 2017-06-23
AU2016379097A1 (en) 2018-06-07
JP6817307B2 (ja) 2021-01-20
SG10202001389PA (en) 2020-04-29
PH12018501355A1 (en) 2019-02-18
AU2021202522C1 (en) 2023-11-23
JP7212198B2 (ja) 2023-01-24
JP2021061845A (ja) 2021-04-22
KR102136678B1 (ko) 2020-07-22
CA3217696A1 (en) 2017-06-23
TW202124414A (zh) 2021-07-01
RU2018122823A (ru) 2020-01-23
PE20232039A1 (es) 2023-12-21
AU2021202522B2 (en) 2023-05-11
US9950058B2 (en) 2018-04-24
AU2019210579B2 (en) 2021-01-28
KR20230035429A (ko) 2023-03-13
AU2019210579A1 (en) 2019-08-22
JP2023015335A (ja) 2023-01-31
PE20181354A1 (es) 2018-08-22
WO2017109629A1 (en) 2017-06-29
US10821171B2 (en) 2020-11-03
KR20180081614A (ko) 2018-07-16
TWI756828B (zh) 2022-03-01
TWI707866B (zh) 2020-10-21
US20210023200A1 (en) 2021-01-28
AU2016379097C1 (en) 2021-04-08
RU2723039C2 (ru) 2020-06-08
US20190125861A1 (en) 2019-05-02
JP2022185022A (ja) 2022-12-13
US20170182151A1 (en) 2017-06-29
KR20200090932A (ko) 2020-07-29
MX2018007622A (es) 2018-11-14
EP3393512A1 (en) 2018-10-31
AU2023214269A1 (en) 2023-10-12
IL260203B1 (en) 2024-05-01
JP7193522B2 (ja) 2022-12-20
JP2019511998A (ja) 2019-05-09
US20230218738A1 (en) 2023-07-13
BR112018010805A2 (pt) 2018-11-27
RU2018122823A3 (es) 2020-01-23
TW201920238A (zh) 2019-06-01
TW202216738A (zh) 2022-05-01
CO2018006301A2 (es) 2018-07-10
CA2952131C (en) 2023-12-05
MX2021007070A (es) 2021-08-11
US20180177864A1 (en) 2018-06-28
KR102505354B1 (ko) 2023-03-02

Similar Documents

Publication Publication Date Title
PE20240817A1 (es) Mutantes de proteina f de rsv
CL2019001000A1 (es) Proteínas de fusión fc heterodiméricas il15/il15ralfa
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
CO2018003863A2 (es) Anticuerpos anti-vegf
BR112017007816A2 (pt) composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas
PH12019500209A1 (en) Methods and compositions for gene expression in plants
PE20161442A1 (es) Proteinas quimericas tipo fosfatasa alcalina
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
EA201691111A1 (ru) Химерные белки фактора viii и их применение
EA201491051A1 (ru) Вакцины против вируса гриппа и их применения
BR112017015833A2 (pt) compostos anti-senescência e usos dos mesmos
MX2023009652A (es) Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras.
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MX2016015594A (es) Productos farmaceuticos mejorados de peptido para resistencia a la insulina.
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
EA201891141A1 (ru) Новые антиангиогенные слитые полипептиды
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
EA202091567A1 (ru) Химерные белки мти
PH12020550099A1 (en) Fusion protein comprising an fgf-18 moiety
EA202191123A1 (ru) Миниатюризированные дистрофины и их применения
AR101555A1 (es) ANTICUERPOS DIRIGIDOS AL RECEPTOR IIB DE Fc g Y AL RECEPTOR DE Fc e
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
BR112019007343A2 (pt) sequência de nucleotídeos expressando uma proteína de ancoragem de exossomo para uso como vacina